Literature DB >> 19647025

A peptidomimetic of NT-3 acts as a TrkC antagonist.

Fouad Brahimi1, Andrey Malakhov, Hong Boon Lee, Mookda Pattarawarapan, Lubijca Ivanisevic, Kevin Burgess, H Uri Saragovi.   

Abstract

Neurotrophins are a family of growth factors that regulate the peripheral and central nervous system. We designed and tested a mini-library of small molecules peptidomimetics based on beta-turns of the neurotrophin growth factor polypeptides NT-3, which is the natural ligand for TrkC receptors. Biological studies identified a peptidomimetic 2Cl that exhibited selective antagonism of TrkC. 2Cl reduces TrkC activation and signaling promoted by NT-3, and selectively blocks ligand-dependent cell survival. 2Cl also blocks ligand-independent TrkC activation and signals that take place when the receptor is over-expressed. This work adds to our understanding of how the neurotrophins function through Trk receptors, and demonstrates that peptidomimetics can be designed to selectively disturb neurotrophin-receptor interactions, and receptor activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19647025      PMCID: PMC2755609          DOI: 10.1016/j.peptides.2009.07.015

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  22 in total

1.  Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight into domain movements upon kinase activation.

Authors:  A Pautsch; A Zoephel; H Ahorn; W Spevak; R Hauptmann; H Nar
Journal:  Structure       Date:  2001-10       Impact factor: 5.006

2.  Syntheses and activities of new C10 beta-turn peptidomimetics.

Authors:  Hong Boon Lee; Maria Clara Zaccaro; Mookda Pattarawarapan; Sudipta Roy; H Uri Saragovi; Kevin Burgess
Journal:  J Org Chem       Date:  2004-02-06       Impact factor: 4.354

Review 3.  Small molecule peptidomimetic ligands of neurotrophin receptors, identifying binding sites, activation sites and regulatory sites.

Authors:  H Uri Saragovi; Maria Clara Zaccaro
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

4.  Rotational dynamics of the epidermal growth factor receptor.

Authors:  Richard A Stein; Eric J Hustedt; James V Staros; Albert H Beth
Journal:  Biochemistry       Date:  2002-02-12       Impact factor: 3.162

5.  High affinity nerve growth factor binding displays a faster rate of association than p140trk binding. Implications for multi-subunit polypeptide receptors.

Authors:  D Mahadeo; L Kaplan; M V Chao; B L Hempstead
Journal:  J Biol Chem       Date:  1994-03-04       Impact factor: 5.157

Review 6.  Signal transduction by the neurotrophin receptors.

Authors:  D R Kaplan; F D Miller
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

7.  p75 Co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains.

Authors:  M C Zaccaro; L Ivanisevic; P Perez; S O Meakin; H U Saragovi
Journal:  J Biol Chem       Date:  2001-06-25       Impact factor: 5.157

Review 8.  The many faces of p75NTR.

Authors:  Barbara L Hempstead
Journal:  Curr Opin Neurobiol       Date:  2002-06       Impact factor: 6.627

9.  Small peptide mimics of nerve growth factor bind TrkA receptors and affect biological responses.

Authors:  L LeSauteur; L Wei; B F Gibbs; H U Saragovi
Journal:  J Biol Chem       Date:  1995-03-24       Impact factor: 5.157

Review 10.  The Trk family of neurotrophin receptors.

Authors:  M Barbacid
Journal:  J Neurobiol       Date:  1994-11
View more
  11 in total

1.  In glaucoma the upregulated truncated TrkC.T1 receptor isoform in glia causes increased TNF-alpha production, leading to retinal ganglion cell death.

Authors:  Yujing Bai; ZhiHua Shi; Yehong Zhuo; Jing Liu; Andrey Malakhov; Eunhwa Ko; Kevin Burgess; Henry Schaefer; Pedro F Esteban; Lino Tessarollo; H Uri Saragovi
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-23       Impact factor: 4.799

2.  Bivalent diketopiperazine-based tropomysin receptor kinase C (TrkC) antagonists.

Authors:  Jing Liu; Fouad Brahimi; H Uri Saragovi; Kevin Burgess
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

3.  Expression of mRNAs for PPT, CGRP, NF-200, and MAP-2 in cocultures of dissociated DRG neurons and skeletal muscle cells in administration of NGF or NT-3.

Authors:  Weiwei Zhang; Hao Li; Ziying Xing; Hongtu Yuan; Mark S Kindy; Zhenzhong Li
Journal:  Folia Histochem Cytobiol       Date:  2012-07-05       Impact factor: 1.698

4.  Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice.

Authors:  Maxime Cazorla; Anne Jouvenceau; Christiane Rose; Jean-Philippe Guilloux; Catherine Pilon; Alex Dranovsky; Joël Prémont
Journal:  PLoS One       Date:  2010-03-19       Impact factor: 3.240

Review 5.  Novel small molecule activators of the Trk family of receptor tyrosine kinases.

Authors:  Obiamaka Obianyo; Keqiang Ye
Journal:  Biochim Biophys Acta       Date:  2012-09-06

6.  Low molecular weight, non-peptidic agonists of TrkA receptor with NGF-mimetic activity.

Authors:  D Scarpi; D Cirelli; C Matrone; G Castronovo; P Rosini; E G Occhiato; F Romano; L Bartali; A M Clemente; G Bottegoni; A Cavalli; G De Chiara; P Bonini; P Calissano; A T Palamara; E Garaci; M G Torcia; A Guarna; F Cozzolino
Journal:  Cell Death Dis       Date:  2012-07-05       Impact factor: 8.469

7.  Combinatorial assembly of small molecules into bivalent antagonists of TrkC or TrkA receptors.

Authors:  Fouad Brahimi; Eunhwa Ko; Andrey Malakhov; Kevin Burgess; H Uri Saragovi
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

8.  From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF).

Authors:  Claire Géral; Angelina Angelova; Sylviane Lesieur
Journal:  Pharmaceutics       Date:  2013-02-08       Impact factor: 6.321

9.  Targeted PDT agent eradicates TrkC expressing tumors via photodynamic therapy (PDT).

Authors:  Chin Siang Kue; Anyanee Kamkaew; Hong Boon Lee; Lip Yong Chung; Lik Voon Kiew; Kevin Burgess
Journal:  Mol Pharm       Date:  2014-12-09       Impact factor: 4.939

10.  The Paradoxical Signals of Two TrkC Receptor Isoforms Supports a Rationale for Novel Therapeutic Strategies in ALS.

Authors:  Fouad Brahimi; Mario Maira; Pablo F Barcelona; Alba Galan; Tahar Aboulkassim; Katrina Teske; Mary-Louise Rogers; Lisa Bertram; Jing Wang; Masoud Yousefi; Robert Rush; Marc Fabian; Neil Cashman; H Uri Saragovi
Journal:  PLoS One       Date:  2016-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.